573 related articles for article (PubMed ID: 20157195)
1. Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations.
Imel EA; DiMeglio LA; Hui SL; Carpenter TO; Econs MJ
J Clin Endocrinol Metab; 2010 Apr; 95(4):1846-50. PubMed ID: 20157195
[TBL] [Abstract][Full Text] [Related]
2. Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status.
Carpenter TO; Insogna KL; Zhang JH; Ellis B; Nieman S; Simpson C; Olear E; Gundberg CM
J Clin Endocrinol Metab; 2010 Nov; 95(11):E352-7. PubMed ID: 20685863
[TBL] [Abstract][Full Text] [Related]
3. Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets.
Alon US; Levy-Olomucki R; Moore WV; Stubbs J; Liu S; Quarles LD
Clin J Am Soc Nephrol; 2008 May; 3(3):658-64. PubMed ID: 18256372
[TBL] [Abstract][Full Text] [Related]
4. A Phex mutation in a murine model of X-linked hypophosphatemia alters phosphate responsiveness of bone cells.
Ichikawa S; Austin AM; Gray AK; Econs MJ
J Bone Miner Res; 2012 Feb; 27(2):453-60. PubMed ID: 22006791
[TBL] [Abstract][Full Text] [Related]
5. Pathogenic role of Fgf23 in Dmp1-null mice.
Liu S; Zhou J; Tang W; Menard R; Feng JQ; Quarles LD
Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E254-61. PubMed ID: 18559986
[TBL] [Abstract][Full Text] [Related]
6. Serum FGF23 levels in normal and disordered phosphorus homeostasis.
Weber TJ; Liu S; Indridason OS; Quarles LD
J Bone Miner Res; 2003 Jul; 18(7):1227-34. PubMed ID: 12854832
[TBL] [Abstract][Full Text] [Related]
7. High iFGF23 level despite hypophosphatemia is one of the clinical indicators to make diagnosis of XLH.
Igaki JM; Yamada M; Yamazaki Y; Koto S; Izawa M; Ariyasu D; Suzuki E; Hasegawa H; Hasegawa Y
Endocr J; 2011; 58(8):647-55. PubMed ID: 21597229
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Effects of FGF23 c-tail Fc in a Murine Preclinical Model of X-Linked Hypophosphatemia Via the Selective Modulation of Phosphate Reabsorption.
Johnson K; Levine K; Sergi J; Chamoun J; Roach R; Vekich J; Favis M; Horn M; Cao X; Miller B; Snyder W; Aivazian D; Reagan W; Berryman E; Colangelo J; Markiewicz V; Bagi CM; Brown TP; Coyle A; Mohammadi M; Magram J
J Bone Miner Res; 2017 Oct; 32(10):2062-2073. PubMed ID: 28600887
[TBL] [Abstract][Full Text] [Related]
9. X-Linked Hypophosphatemia: Uniquely Mild Disease Associated With PHEX 3'-UTR Mutation c.*231A>G (A Retrospective Case-Control Study).
Smith PS; Gottesman GS; Zhang F; Cook F; Ramirez B; Wenkert D; Wollberg V; Huskey M; Mumm S; Whyte MP
J Bone Miner Res; 2020 May; 35(5):920-931. PubMed ID: 31910300
[TBL] [Abstract][Full Text] [Related]
10. Intact Fibroblast Growth Factor 23 Concentrations in Hypophosphatemic Disorders.
Ramos P; Larson B; Ashrafzadeh-Kian S; Ito N; Kato H; Bornhorst JA; Algeciras-Schimnich A
Endocr Pract; 2023 Mar; 29(3):193-198. PubMed ID: 36627024
[TBL] [Abstract][Full Text] [Related]
11. Plasma intact fibroblast growth factor 23 level is a useful tool for diagnostic approach of renal hypophosphatemia.
Giralt M; Chocron S; Ferrer R; Ariceta G
Pediatr Nephrol; 2021 Apr; 36(4):1025-1028. PubMed ID: 33492457
[TBL] [Abstract][Full Text] [Related]
12. FGF23 and Associated Disorders of Phosphate Wasting.
Gohil A; Imel EA
Pediatr Endocrinol Rev; 2019 Sep; 17(1):17-34. PubMed ID: 31599133
[TBL] [Abstract][Full Text] [Related]
13. Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment.
Endo I; Fukumoto S; Ozono K; Namba N; Inoue D; Okazaki R; Yamauchi M; Sugimoto T; Minagawa M; Michigami T; Nagai M; Matsumoto T
Endocr J; 2015; 62(9):811-6. PubMed ID: 26135520
[TBL] [Abstract][Full Text] [Related]
14. 1,25-Dihydroxyvitamin D Alone Improves Skeletal Growth, Microarchitecture, and Strength in a Murine Model of XLH, Despite Enhanced FGF23 Expression.
Liu ES; Martins JS; Raimann A; Chae BT; Brooks DJ; Jorgetti V; Bouxsein ML; Demay MB
J Bone Miner Res; 2016 May; 31(5):929-39. PubMed ID: 26751835
[TBL] [Abstract][Full Text] [Related]
15. Iron and fibroblast growth factor 23 in X-linked hypophosphatemia.
Imel EA; Gray AK; Padgett LR; Econs MJ
Bone; 2014 Mar; 60():87-92. PubMed ID: 24325979
[TBL] [Abstract][Full Text] [Related]
16. The expanding family of hypophosphatemic syndromes.
Carpenter TO
J Bone Miner Metab; 2012 Jan; 30(1):1-9. PubMed ID: 22167381
[TBL] [Abstract][Full Text] [Related]
17. FGF23 and its role in X-linked hypophosphatemia-related morbidity.
Beck-Nielsen SS; Mughal Z; Haffner D; Nilsson O; Levtchenko E; Ariceta G; de Lucas Collantes C; Schnabel D; Jandhyala R; Mäkitie O
Orphanet J Rare Dis; 2019 Feb; 14(1):58. PubMed ID: 30808384
[TBL] [Abstract][Full Text] [Related]
18. New Therapies for Hypophosphatemia-Related to FGF23 Excess.
Athonvarangkul D; Insogna KL
Calcif Tissue Int; 2021 Jan; 108(1):143-157. PubMed ID: 32504139
[TBL] [Abstract][Full Text] [Related]
19. Effects of Burosumab Treatment on Two Siblings with X-Linked Hypophosphatemia. Case Report and Literature Review.
Jurca CM; Iuhas O; Kozma K; Petchesi CD; Zaha DC; Bembea M; Jurca S; Paul C; Jurca AD
Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011303
[TBL] [Abstract][Full Text] [Related]
20. Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia.
Linglart A; Imel EA; Whyte MP; Portale AA; Högler W; Boot AM; Padidela R; Van't Hoff W; Gottesman GS; Chen A; Skrinar A; Scott Roberts M; Carpenter TO
J Clin Endocrinol Metab; 2022 Feb; 107(3):813-824. PubMed ID: 34636899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]